Cardiovascular Disease Drug Market Propelled by Rise in Prevalence of Cardiovascular Diseases

A cardiovascular disease (CVD) is a disorder related to blood vessels and the heart. Stroke, atherosclerosis, peripheral artery disease, thrombosis, and coronary artery disease are some of the most common cardiovascular diseases. Cardiovascular diseases are among the deadliest diseases in the world. Obesity, smoking, unhealthy lifestyle, high cholesterol, and excess intake of alcohol are some of the causes of and factors associated with cardiovascular diseases. As per the World Health Organization, cardiovascular diseases are responsible for around 15 mn deaths every year, globally. The increasing incidence of cardiovascular diseases will drive the global cardiovascular disease drug market during the period from 2015 to 2023. 
 
Antihypertensive Drug Class to Lead Global Cardiovascular Disease Drug Market
 
The global cardiovascular disease drug market is segmented on the basis of geography and drug class. By drug class, the global cardiovascular disease drug market was dominated by the antihypertensive drugs sector in 2014. The presence of a wide variety of multibillion-dollar medicines such as Benicar and Diovan will help the antihypertensive drugs sector maintain its dominant position in the global cardiovascular disease drug market till 2023.

Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5150

Availability of various medicines to cure cardiovascular diseases is expected to boost the global cardiovascular disease drug market during the forecast period. Some of the effective drugs used for treating cardiovascular diseases are heparin, Sectral (acebutolol), Lopressor, Norvasc, Coumadin (warfarin), Zebeta (bisoprolol), Lotrel (amlodipine), Sular (nisoldipine), Toprol XL (metoprolol), and others. 
 
The global cardiovascular disease drug market is divided by drug class,  mechanism of action, and indications. Based on mechanism, the global cardiovascular disease drug market is divided into beta blockers, alpha blockers, beta agonists, calcium channel blockers, sodium channel blockers, renin inhibitors, diuretics, angiotensin receptor blockers, and thrombolytics. Based on indications, the global cardiovascular disease drug market is divided into stroke, dyslipidemia, and hypertension. 
 
Increasing Cases of Heart Attacks in North America to Boost Global CVD Market
 
By geography, the global cardiovascular disease drug market is divided into regions such as Latin America, Asia Pacific, North America, Europe, and Rest of the World. In 2013, the North America cardiovascular disease drug market dominated the global cardiovascular disease drug market. According to the reports from the Center for Disease Control and Prevention (CDC), in North America, around 610,000 people die every year due to heart diseases. Every year, around 735,000 residents of the U.S. suffer from heart attacks. Increasing number of heart attacks and other cardiovascular diseases in North America will propel the demand for cardiovascular medicines and treatments in this region during the forecast period. The Asia Pacific cardiovascular disease drug market is predicted to record the fastest growth due to the recent increase in the number of elderly people and increase in awareness about cardiovascular diseases, their debilitating effect on one’s life, and their treatment.   
 
Some of the leading companies in the global cardiovascular disease drug market are AstraZeneca Plc, Sanofi S.A., Daiichi Sankyo Company Limited, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., United Therapeutics Corporation, Roche Holding AG, Pfizer, Inc., Merck & Co., Novartis AG, Boehringer Ingelheim GmbH, Johnson & Johnson, Actelion Pharmaceuticals Ltd., and Bayer AG. 
 
Browse Full Global Cardiovascular Disease Drug Market  Research Report With Complete TOC @ http://www.transparencymarketresearch.com/retractable-safety-syringes.html

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:

Mr. Nachiket Ghumare
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com